Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05280314
Title Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab in Patients With Resectable Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors IO Biotech
Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DEU | AUS

No variant requirements are available.